Detection of Tumor ALK Status in Neuroblastoma Patients Using Peripheral Blood

Overview

Journal Cancer Med

Specialty Oncology

Date 2015 Feb 6

PMID 25653133

Citations 42

Authors

Valerie Combaret

Isabelle Iacono

Angela Bellini

Stephanie Brejon

Virginie Bernard

Aurelien Marabelle

Carole Coze

Gaelle Pierron

Eve Lapouble

Gudrun Schleiermacher

Jean Yves Blay

Affiliations

Soon will be listed here.

Abstract

New protocols based on ALK-targeted therapy by crizotinib or other ALK-targeting molecules have opened for the treatment of patients with neuroblastoma (NB) if their tumors showed mutation and/or amplification of the ALK gene. However, tumor samples are not always available for analysis of ALK mutational status in particular at relapse. Here, we evaluated the ALK mutational status of NB samples by analysis of circulating DNA, using the droplet digital PCR (ddPCR) system. ddPCR assays was developed for the detection of ALK mutations at F1174 and R1275 hotspots found in NB tumors and was applied for the analysis of circulating DNA obtained from 200 μL of serum or plasma samples collected from 114 patients with NB. The mutations F1174L (exon 23 position 3520, T>C and position 3522, C>A) and the mutation R1275Q (exon 25 position 3824, G>A) were detected in circulating DNA. The sensitivity of our test was 100%, 85%, and 92%, respectively, and the specificity was 100%, 91%, and 98%, respectively. In conclusion, the assay that we have developed offers a reliable, noninvasive blood test to assess ALK mutational status at F1174 and R1275 hotspots and should help clinicians to identify patients showing an ALK mutation in particular when no tumor tissue is available.

Citing Articles

Personalized circulating tumor DNA analysis for sensitive disease monitoring and detection of relapse in neuroblastoma.

Rahmqvist I, Engstrom E, Mellstrom E, Ibrahim R, Pujol-Calderon F, Dahlstrand Rudin A Biomark Res. 2024; 12(1):148.

PMID: 39593169 PMC: 11600567. DOI: 10.1186/s40364-024-00688-5.

A comprehensive overview of liquid biopsy applications in pediatric solid tumors.

Janssen F, Lak N, Janda C, Kester L, Meister M, Merks J NPJ Precis Oncol. 2024; 8(1):172.

PMID: 39097671 PMC: 11297996. DOI: 10.1038/s41698-024-00657-z.

Advances in liquid biopsy in neuroblastoma.

Zhuo Z, Lin L, Miao L, Li M, He J Fundam Res. 2024; 2(6):903-917.

PMID: 38933377 PMC: 11197818. DOI: 10.1016/j.fmre.2022.08.005.

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.

Bobin C, Iddir Y, Butterworth C, Masliah-Planchon J, Saint-Charles A, Bellini A Clin Cancer Res. 2024; 30(15):3316-3328.

PMID: 38787533 PMC: 11292203. DOI: 10.1158/1078-0432.CCR-24-0753.

Integrative analysis of multi-omics data for discovery of ferroptosis-related gene signature predicting immune activity in neuroblastoma.

Hu J, Song F, Kang W, Xia F, Song Z, Wang Y Front Pharmacol. 2023; 14:1162563.

PMID: 37521469 PMC: 10373597. DOI: 10.3389/fphar.2023.1162563.

References

Chan K, Jiang P, Zheng Y, Liao G, Sun H, Wong J . Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. 2012; 59(1):211-24. DOI: 10.1373/clinchem.2012.196014. View

Sausen M, Leary R, Jones S, Wu J, Reynolds C, Liu X . Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2012; 45(1):12-7. PMC: 3557959. DOI: 10.1038/ng.2493. View

Barone G, Anderson J, Pearson A, Petrie K, Chesler L . New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clin Cancer Res. 2013; 19(21):5814-21. PMC: 3818140. DOI: 10.1158/1078-0432.CCR-13-0680. View

Beaver J, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky D . Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014; 20(10):2643-2650. PMC: 4024333. DOI: 10.1158/1078-0432.CCR-13-2933. View

Page K, Guttery D, Zahra N, Primrose L, Elshaw S, Pringle J . Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One. 2013; 8(10):e77963. PMC: 3799744. DOI: 10.1371/journal.pone.0077963. View

Chen Y, Takita J, Choi Y, Kato M, Ohira M, Sanada M . Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008; 455(7215):971-4. DOI: 10.1038/nature07399. View

Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Frio T . Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol. 2014; 32(25):2727-34. DOI: 10.1200/JCO.2013.54.0674. View

Moore N, Azarova A, Bhatnagar N, Ross K, Drake L, Frumm S . Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014; 5(18):8737-49. PMC: 4226718. DOI: 10.18632/oncotarget.2372. View

George R, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J . Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008; 455(7215):975-8. PMC: 2587486. DOI: 10.1038/nature07397. View

10.

Combaret V, Audoynaud C, Iacono I, Favrot M, Schell M, Bergeron C . Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res. 2002; 62(13):3646-8. View

11.

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

12.

Delacour H, Servonnet A, Perrot A, Vigezzi J, Ramirez J . [ROC (receiver operating characteristics) curve: principles and application in biology]. Ann Biol Clin (Paris). 2005; 63(2):145-54. View

13.

Gotoh T, Hosoi H, Iehara T, Kuwahara Y, Osone S, Tsuchiya K . Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol. 2005; 23(22):5205-10. DOI: 10.1200/JCO.2005.02.014. View

14.

Combaret V, Bergeron C, Noguera R, Iacono I, Puisieux A . Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol. 2005; 23(34):8919-20. DOI: 10.1200/JCO.2005.04.0170. View

15.

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

16.

Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, De Pontual L, Combaret V . Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455(7215):967-70. DOI: 10.1038/nature07398. View

17.

Mosse Y, Lim M, Voss S, Wilner K, Ruffner K, Laliberte J . Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14(6):472-80. PMC: 3730818. DOI: 10.1016/S1470-2045(13)70095-0. View

18.

Caren H, Abel F, Kogner P, Martinsson T . High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008; 416(2):153-9. DOI: 10.1042/bj20081834. View

19.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

20.

Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D . Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009; 27(7):1026-33. DOI: 10.1200/JCO.2008.16.0630. View